『The Lancet Haematology in conversation with』のカバーアート

The Lancet Haematology in conversation with

The Lancet Haematology in conversation with

著者: The Lancet Group
無料で聴く

このコンテンツについて

Lan-Lan Smith, Editor-in-Chief, Cheryl Lai, Acting Deputy Editor, and Emma Cookson, Senior Editor at The Lancet Haematology, in conversation with the journal’s authors, explore their latest research and its impact on people’s health, healthcare, and health policy.

A monthly audio companion to the journal, this podcast covers a broad range of topics, from racial and ethnic disparities in leukaemia survival outcomes to resuscitation with blood products compared with saline, the link between mental health and lymphoma to haemolytic disease in newborns, and more.

© 2025 The Lancet Group
生物科学 科学 衛生・健康的な生活 身体的病い・疾患
エピソード
  • Paolo Strati on off-the-shelf induced pluripotent stem-cell-derived natural killer-cell therapy for patients with relapsed or refractory B-cell lymphoma
    2025/07/01

    Associate Professor Paolo Strati (Department of Lymphoma and Myeloma, and Department of Translational Molecular Pathology, University of Texas MD Anderson Cancer Center, Houston, TX, USA) joins us to discuss the results of a multicentre, open-label, phase 1 clinical trial of off-the-shelf induced pluripotent stem-cell-derived natural killer-cell therapy for patients with relapsed or refractory B-cell lymphoma.

    Read the full article:

    https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026(25)00142-5/fulltext?dgcid=buzzsprout_icw_podcast_July_25_lanhae

    Continue this conversation on social!
    Follow us today at...
    https://thelancet.bsky.social/
    https://instagram.com/thelancetgroup
    https://facebook.com/thelancetmedicaljournal
    https://linkedIn.com/company/the-lancet
    https://youtube.com/thelancettv

    続きを読む 一部表示
    22 分
  • A panel of the authors on our Adverse Events Series on adverse event reporting in haematological malignancies
    2025/06/13

    With a growing number of treatment options for blood cancers, understanding the side effects from these treatments and how they affect patients is becoming ever more important. Join a panel of authors from The Lancet Haematology's latest series on Adverse Event reporting to discuss how we can improve clinical trial design and analysis, and translate this data to meaningful, patient-centric care.

    Read the full series here:
    https://www.thelancet.com/series-do/adverse-events-in-haematology-oncology?dgcid=buzzsprout_icw_podcast_13-06-25_lanhaeadverseevents25_lanhae

    Continue this conversation on social!
    Follow us today at...
    https://thelancet.bsky.social/
    https://instagram.com/thelancetgroup
    https://facebook.com/thelancetmedicaljournal
    https://linkedIn.com/company/the-lancet
    https://youtube.com/thelancettv

    続きを読む 一部表示
    40 分
  • Michael Northend on early rituximab monotherapy versus watchful waiting for advanced stage, asymptomatic, low tumour burden follicular lymphoma
    2025/04/28

    Dr Michael Northend (University College London Hospitals NHS Foundation Trust, and Cancer Research UK & UCL Cancer Trials Centre, London, UK) joins us to discuss the long-term results of a randomised, phase 3 trial on early rituximab monotherapy versus watchful waiting for advanced stage, asymptomatic, low tumour burden follicular lymphoma.

    Read the full article:

    https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026(25)00034-1/fulltext?dgcid=buzzsprout_icw_podcast_28-04-25_lanhae

    Continue this conversation on social!
    Follow us today at...
    https://thelancet.bsky.social/
    https://instagram.com/thelancetgroup
    https://facebook.com/thelancetmedicaljournal
    https://linkedIn.com/company/the-lancet
    https://youtube.com/thelancettv

    続きを読む 一部表示
    16 分
まだレビューはありません